Article Text

other Versions

PDF
Treatment of lateral epicondylitis using skin-derived tenocyte-like cells
  1. David Connell (david.connell{at}rnoh.nhs.uk)
  1. Royal National Orthopaedic Hospital, United Kingdom
    1. Abhijit Datir (apdatir{at}gmail.com)
    1. Royal National Orthopaedic Hospital, United Kingdom
      1. Faisal Alyas (faisal.alyas{at}gmail.com)
      1. Royal National Orthopaedic Hospital, United Kingdom
        1. Mark Curtis
        1. Kingston Hospital NHS Trust, Kinston-upon-Thames, United Kingdom

          Abstract

          Objectives: (1) To culture collagen-producing cells derived from skin fibroblasts and, (2) To evaluate prospectively the safety and potential use of this cell preparation for treatment of refractory lateral epicondylitis (CEO tendinosis) in a pilot study.

          Design: Prospective clinical pilot study.

          Setting: Institution based clinical research.

          Patients: Twelve patients (5 men and 7 women; mean age 39.1 years) with clinical diagnosis of refractory lateral epicondylitis.

          Interventions: Laboratory-prepared collagen-producing cells derived from dermal fibroblasts were injected into the sites of intra-substance tears and fibrillar discontinuity of the common extensor origin under ultrasound guidance.

          Main outcome measurements: The outcome assessment was done over 6 months using (i) Patient-Rated Tennis Elbow Evaluation scale for pain severity and functional disability and (ii), the tendon healing response was measured using four criteria on ultrasound – tendon thickness, hypoechogenicity, intra-substance tears and neovascularity.

          Results: Successful preparation of cell cultures rich in collagen-producing cells was possible in laboratory. After injection, the median PRTEE score decreased from 78 pre-procedure status to 47 at 6weeks, 35 at 3months and 12 at 6months (p<0.05). The healing response on ultrasound showed median decrease in – (a) number of tears from 5 to 2, (b) number of new vessels from 3 to 1 and, (c) tendon thickness from 4.35 to 4.2 (p<0.05). Eleven of the 12 patients had a satisfactory outcome such that only one patient proceeded to surgery following failure of treatment at the end of 3months.

          Conclusions: Skin-derived tenocyte-like cells can be cultured in the laboratory to yield a rich preparation of collagen-producing cells. Our pilot study suggests that these collagen-producing cells can be injected safely and may have therapeutic value in patient’s suffering from refractory CEO tendinosis.

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

          Linked Articles